Long term outcomes of patients with tuberculous meningitis: The impact of drug resistance

• Authors: Emily E Evans, Emory University; Teona Avaliani, National Center for Tuberculosis and Lung Diseases; Mariam Gujabidze, National Center for Tuberculosis and Lung Diseases; Tinatin Bakuradze, National Center for Tuberculosis and Lung Diseases; Maia Kipiani, National Center for Tuberculosis and Lung Diseases; Shorena Sabanadze, National Center for Tuberculosis and Lung Diseases; Alison GC Smith, Emory University; Zaza Avaliani, National Center for Tuberculosis and Lung Diseases; Jeffrey Collins, Emory University; Russell Kempker, Emory University
• Journal Title: PLOS ONE
• Volume: Volume 17, Number 6
• Publisher: PUBLIC LIBRARY SCIENCE | 2022-06-30, Pages e0270201-e0270201
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1371/journal.pone.0270201
• Subjects: Health Sciences, Medicine and Surgery
• Keywords: Science & Technology; Multidisciplinary Sciences; Science & Technology - Other Topics; CEREBROSPINAL-FLUID

Abstract

Background Little is known about the impact of drug-resistance on clinical outcomes among patients with tuberculosis meningitis (TBM). Methods A retrospective cohort study among patients treated for TBM in Tbilisi, Georgia. We performed medical chart abstraction to collect patient data. Long-term vital status was assessed using the Georgia National Death Registry. We utilized a Cox proportional-hazards model to evaluate the association of drug-resistance and mortality. Results Among 343 TBM suspects, 237 had a presentation consistent with TBM. Drug resistance was suspected (n = 5) or confirmed (n = 31) in 36 patients including 30 with multidrug- or rifampin-resistance and 6 with isoniazid-resistance. Thirty-four patients had HIV. The median follow-up time was 1331 days (IQR, 852–1767). Overall, 73 of 237 (30%) people died with 50 deaths occurring during and 23 after treatment. The proportion of death was higher among patients with drug-resistant vs. drug-susceptible disease (67% vs. 24%, p<0.001) and with HIV versus no HIV (59% vs 27%, p<0.001). Mortality was significantly higher in patients with drug-resistant TBM after 90 days of treatment (aHR = 7.2, CI95% [3.6–14.3], p < 0.001). Conclusions Mortality was high among patients with drug-resistant TBM with many deaths occurring post treatment. More effective treatment options are urgently needed for drug-resistant TBM.